What Is The New Drug For Lung Cancer In 2024?
In 2024, several new lung cancer treatments, including Unecritinib Fumarate Capsules, Tarlatamab, Zenocutuzumab, Lazertinib and Amivantamab Combination, and Durvalumab, were approved, offering groundbreaking options for patients with various types of lung cancer.
| Drug Name | Brand Name | Approval Date | Indication | Mechanism of Action |
|---|---|---|---|---|
| Unecritinib Fumarate Capsules | Amberni | April 30, 2024 | ROS1-positive advanced or metastatic non-small cell lung cancer (NSCLC) | Small molecule tyrosine kinase inhibitor targeting ROS1, ALK, and c-Met to inhibit tumor growth. |
| Tarlatamab | Imdelltra | May 2024 | Extensive-stage small cell lung cancer (SCLC) | Immunotherapy targeting the DLL3 protein on cancer cells. |
| Zenocutuzumab | Bizengri | December 4, 2024 | Advanced, unresectable, or metastatic NSCLC with NRG1 gene fusion | Targets the HER3 protein to inhibit tumor cell growth. |
| Lazertinib and Amivantamab Combination | – | August 2024 | Locally advanced or metastatic NSCLC with specific EGFR mutations | Combination therapy targeting EGFR mutations to inhibit tumor growth. |
| Durvalumab (Imfinzi) | Imfinzi | December 4, 2024 | Limited-stage SCLC whose disease has not progressed after chemotherapy and radiation therapy | PD-L1 inhibitor enhancing the immune system’s ability to fight cancer. |
These approvals represent significant advancements in lung cancer treatment, providing new options for patients with various types and stages of the disease on dengyuemed.